Catalog No. size PriceQuantity
M6418-2 2mg solid $130
M6418-10 10mg solid $531


Su-11274 is a selective Met tyrosine kinase inhibitor with IC50 of 10 nM. Su-11274 increases tumorigenicity and enriched for melanoma-initiating cells by bioenergetic modulation. Su-11274 suppresses proliferation and motility of pancreatic cancer cells. Su-11274 enhances the response of the prostate cancer cell line DU145 to ionizing radiation. Su-11274 exhibits a selective inhibition pattern toward different receptor mutated variants.

Product information

CAS Number: 658084-23-2

Molecular Weight: 568.09

Formula: C28H30ClN5O4S


SU 11274



Chemical Name: (3Z)-N-(3-Chlorophenyl)-3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-methyl-2-oxo-1H-indole-5-sulfonamide

Smiles: CN1CCN(CC1)C(=O)C1C(C)=C(/C=C2/C3=CC(=CC=C3NC/2=O)S(=O)(=O)N(C)C2=CC(Cl)=CC=C2)NC=1C


InChi: InChI=1S/C28H30ClN5O4S/c1-17-25(30-18(2)26(17)28(36)34-12-10-32(3)11-13-34)16-23-22-15-21(8-9-24(22)31-27(23)35)39(37,38)33(4)20-7-5-6-19(29)14-20/h5-9,14-16,30H,10-13H2,1-4H3,(H,31,35)/b23-16-

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Soluble in DMSO, not in water

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined.

HS Tariff Code: 382200

How to use

In Vitro:

Su-11274 exhibits greater than 50-fold selectivity for Met versus Flk and more than 500 times selectivity versus other tyrosine kinases such as FGFR-1, c-src, PDGFbR, and EGFR. Su-11274 inhibits the phosphorylation of key regulators of the PI3K pathway, including AKT, FKHR, or GSK3β. Su-11274 treatment inhibits the growth of TPR-MET-transformed BaF3 cells in a dose-dependent manner with IC50 of < 3 μM in the absence of interleukin 3, without growth inhibition of BaF3 cells transformed by other oncogenic tyrosine kinases, including BCR-ABL, TEL-JAK2, TEL-ABL, and TEL-PDGFβR. In addition to cell growth, Su-11274 treatment significantly inhibits the migration of BaF3. TPR-MET cells by 44.8% and 80% at 1 μM and 5 μM, respectively. Su-11274 inhibits HGF-dependent phosphorylation of Met as well as HGF-dependent cell proliferation and motility with an IC50 of 1-1.5 μM. In H69 and H345 cells which have functional Met receptor, Su-11274 inhibits the HGF-induced cell growth with IC50 of 3.4 μM and 6.5 μM, respectively. Su-11274 induces G1 cell cycle arrest with cells in G1 phase increased from 42.4% to 70.6% at 5 μM, and induces caspase-dependent apoptosis by 24% at 1 μM. Su-11274 inhibits cell viability in c-Met-expressing non-small cell lung cancer (NSCLC) cells with IC50 values of 0.8-4.4 μM, and abrogates hepatocyte growth factor-induced phosphorylation of c-Met and its downstream signaling.


  1. Kucerova L, Demkova L, Skolekova S, Bohovic R, Matuskova M. Tyrosine kinase inhibitor SU11274 increased tumorigenicity and enriched for melanoma-initiating cells by bioenergetic modulation. BMC Cancer. 2016 May 12;16:308. doi: 10.1186/s12885-016-2341-y. PubMed PMID: 27175734; PubMed Central PMCID: PMC4866285.
  2. Tomizawa M, Shinozaki F, Motoyoshi Y, Sugiyama T, Yamamoto S, Ishige N. SU11274 suppresses proliferation and motility of pancreatic cancer cells. Oncol Lett. 2015 Sep;10(3):1468-1472. Epub 2015 Jul 2. PubMed PMID: 26622692; PubMed Central PMCID: PMC4533741.
  3. Tomizawa M, Shinozaki F, Motoyoshi Y, Sugiyama T, Yamamoto S, Ishige N. Co-culture of hepatocellular carcinoma cells and human umbilical endothelial cells damaged by SU11274. Biomed Rep. 2014 Nov;2(6):799-803. Epub 2014 Sep 10. PubMed PMID: 25279148; PubMed Central PMCID: PMC4179721.
  4. Gao SH, Liu C, Wei J, Feng Y. Effect of c-Met inhibitor SU11274 on human colon cancer cell growth. Chin Med J (Engl). 2013 Jul;126(14):2705-9. PubMed PMID: 23876900.
  5. Gao W, Bing X, Li M, Yang Z, Li Y, Chen H. Study of critical role of c-Met and its inhibitor SU11274 in colorectal carcinoma. Med Oncol. 2013 Jun;30(2):546. doi: 10.1007/s12032-013-0546-3. Epub 2013 Mar 28. PubMed PMID: 23536000.

Products are for research use only. Not for human use.

Payment & Security

PayPal Venmo

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed